AstraZeneca Pays US$200 M Upfront for Ionis’ Rare Disease Drug

By Lucy Haggerty

Pharma Deals Review: Vol 2021 Issue 12 (Table of Contents)

Published: 15 Dec-2021

DOI: 10.3833/pdr.v2021.i12.2650     ISSN: 1756-7874

Section: Licensing



Building its rare disease presence, AstraZeneca has agreed to collaborate with Ionis Pharmaceuticals to develop and commercialise the latter’s Phase III antisense drug, eplontersen...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details